HALCON Unveils UAE’s First Air Defence Missile
23.2.2021 19:40:00 EET | Business Wire | Press release
HALCON, a regional leader in the production and supply of precision-guided weapons, today unveiled SkyKnight - the first UAE designed and manufactured counter-rocket, artillery, and mortar (C-RAM) missile system, at the International Defence and Exhibition Conference (IDEX) 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005887/en/
SkyKnight - the first UAE designed and manufactured counter-rocket, artillery, and mortar (C-RAM) missile system - (Photo: AETOSWire)
EDGE, the parent company of HALCON, has been developing a short-range air defence system, as has Germany-based Rheinmetall AG, which was actively seeking a missile system to form part of its Skynex air defence system. The companies decided to jointly offer a solution, with HALCON providing SkyKnight, the missile system to the highly regarded Oerlikon Skynex Air Defence System, which sets new standards with its unique open architecture.
HALCON’s SkyKnight was purposely designed to counter the full spectrum of modern threats, providing early warning signals and precise surface-to-air intercept capabilities targeting of rotary-wing aircraft, unmanned aerial vehicles (UAVs) rockets, artillery, mortar, and other fixed-wing aircraft at a range of up to 10Km.
Commenting on this landmark international elevation of a UAE-manufactured missile, H.E. Faisal Al Bannai, EDGE Group CEO and Managing Director said: “SkyKnight is the UAE’s first, but will not be the last air defence missile developed by HALCON. We are pleased to team up with Rheinmetall, a leading player in the defence industry, for us to jointly offer the world’s most advanced and comprehensive C-RAM solution leveraging our SkyKnight missile and Rheinmetall’s Skynex solution. This collaboration is a clear message that EDGE is open to teaming up with various players to offer joint advance solutions.”
The Oerlikon Skynex air defence system comprises the Oerlikon Skynex control node, multi-sensor units (MSU) featuring active electronically scanned multi-mode radars (AMMR), multiple 35mm revolver guns RG Mk3 and HALCON’s SkyKnight C-RAM missiles and missile launchers, each of which has a capacity of 60 missiles. HALCON’s C-RAM missile is capable of tracking and neutralising numerous, multi-directional incoming targets at one time, providing protection for static assets, as well as for mobile and mechanised forces. Transportable and mobile, the system can be deployed fixed on land, sea and moving land platform.
Rheinmetall AG, through its Swiss subsidiary, Rheinmetall Air Defence, has deployed the Skyguard system in numerous countries, which can bring down fast, small targets, and is used as the inner tier of layered air defence of vital points and critical military infrastructure. Countries that have rolled out Skyguard systems will ultimately upgrade to Skynex, placing HALCON, its SkyKnight C-RAM missile system, and the UAE at the forefront of air defence system innovation.
HALCON is part of the Missiles & Weapons cluster within EDGE, an advanced technology group for defence that ranks among the top 25 military suppliers in the world.
About EDGE
EDGE is an advanced technology group established to develop agile, bold and disruptive solutions for defence and beyond. Enabling a secure future, it is dedicated to bringing innovative technologies and services to market with greater speed and efficiency. Consolidating over 25 entities and employing more than 13,000 brilliant minds, it offers expertise across five core clusters: Platforms & Systems, Missiles & Weapons, Cyber Defence, Electronic Warfare & Intelligence and Mission Support. Headquartered in Abu Dhabi, United Arab Emirates, EDGE is a catalyst for change – set to revolutionise the industry and change its fundamentals.
For more information, visit edgegroup.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005887/en/
Contact information
EDGE Group Press Office
Thushara Mohanan,
media@edgegroup.ae
+971555080413
+971553584520
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom